๐ŸŒ EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

30 recruiting trials

for Locally Advanced, Recurrent or Metastatic Malignancies

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment. NCT07062965Phase 3433 sites๐Ÿ“ Anchorage๐Ÿ“ Chandler๐Ÿ“ Gilbert Pfizer ยท Tests: PF-07248144, Fulvestrant, Everolimus, Exemestane PG2 Injection for the Treatment of moderate-to Severe Fatigue in Breast Cancer Patients NCT05440227Phase 21 site๐Ÿ“ Taipei PhytoHealth Corporation ยท Tests: PG2 Lyo. Injection 500mg, Placebo 0.9% normal saline RGL-270 + ICI in Advanced NSCLC NCT07652125NA1 site๐Ÿ“ Guangzhou Guangdong Association of Clinical Trials ยท Tests: RGL-270 in Combination with PD-1/PD-L1 Inhibitors, Physician's Choice SOC Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer NCT06982521Phase 3243 sites๐Ÿ“ Gilbert๐Ÿ“ Beverly Hills๐Ÿ“ Duarte Relay Therapeutics, Inc. ยท Tests: Zovegalisib, Capivasertib, Fulvestrant A Dose-Expansion Trial of Intravenous HNF4ฮฑ srRNA for Unresectable or Metastatic Colorectal Cancer NCT07050394EARLY Phase 11 site๐Ÿ“ Shanghai Shanghai Changzheng Hospital ยท Tests: CD-GA-102 Study of ACR-2316 in Specific Advanced Solid Tumors NCT06667141Phase 1, Phase 215 sites๐Ÿ“ Phoenix๐Ÿ“ Beverly Hills๐Ÿ“ Newport Beach Acrivon Therapeutics ยท Tests: ACR-2316 Pembrolizumab Combination With Lenvatinib in Pts With Recurrent,Persistent,Metastatic or Locally Advanced Vulvar Cancer Not Amenable to Curative Surgery or Radiotherapy NCT05903833Phase 215 sites๐Ÿ“ Augsburg๐Ÿ“ Bad Homburg๐Ÿ“ Dresden AGO Research GmbH ยท Tests: Pembrolizumab, Lenvatinib A Study of MR001 in Patients With Locally Recurrent or Metastatic Advanced Triple-Negative Breast Cancer (TNBC) NCT07208149Phase 1, Phase 21 site๐Ÿ“ Beijing Shenzhen Majory Biotechnology Co., Ltd. ยท Tests: MR001 Bispecific Antibody for Injection An Open-label, Single-arm Study of Prophylaxis for Datopotamab Deruxtecan (Dato-DXd) -Related Stomatitis in Eligible Patients With Metastatic or Inoperable Locally Recurrent Breast Cancer or Locally Advanced or Metastatic Epidermal Growth Factor Receptor-Mutated Non-small Cell Lung Cancer. NCT07357597Phase 441 sites๐Ÿ“ Tucson๐Ÿ“ Hot Springs๐Ÿ“ Little Rock AstraZeneca ยท Tests: Dexamethasone mouthwash, Datopotamab Deruxtecan (Dato-DXd) A Study on the Efficacy and Safety of Oral All-trans Retinoic Acid Combined With Toripalimab in TNBC. NCT06371274NA1 site๐Ÿ“ Hangzhou First Affiliated Hospital of Zhejiang University ยท Tests: ATRA, Toripalimab Study of Larotinib in Unresectable Advanced or Recurrent Esophageal Cancer NCT04415853Phase 31 site๐Ÿ“ Beijing Sunshine Lake Pharma Co., Ltd. ยท Tests: Lerotinib, Irinotecan/Tegafur Treatment With Amivantamab and Hyaluronidase or Cetuximab for Advanced Skin Cancer in People With a Weakened Immune System NCT07042295Phase 255 sites๐Ÿ“ Birmingham๐Ÿ“ Gilbert๐Ÿ“ La Jolla National Cancer Institute (NCI) ยท Tests: Amivantamab and Recombinant Human Hyaluronidase, Biospecimen Collection, Cetuximab, Computed Tomography, Magnetic Resonโ€ฆ Phase II Study of Trastuzumab Rezetecan or in Combination With Adebrelimab in HER2-Expressing Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC) NCT07241793Phase 26 sites๐Ÿ“ Guangzhou๐Ÿ“ Guangzhou๐Ÿ“ Guangzhou Sun Yat-sen University ยท Tests: Adebrelimab, Trastuzumab Rezetecan SSGJ-705 Monotherapy and Combination Therapy in Advanced HER2-Expressing Solid Tumors NCT07022002Phase 21 site๐Ÿ“ Hangzhou Shenyang Sunshine Pharmaceutical Co., LTD. ยท Tests: SSGJ-705, PD-1/L1 inhibitor combined with chemotherapy, SSGJ-705 combined with chemotherapy Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatment NCT02029001Phase 27 sites๐Ÿ“ Bordeaux๐Ÿ“ Lyon๐Ÿ“ Lyon Centre Leon Berard ยท Tests: Nilotinib (400 mg BID), Everolimus (10 mg QD), Sorafenib (400 mg BID), Lapatinib (1500 mg QD), Pazopanib (800 mg QD) Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer NCT06081959Phase 31 site๐Ÿ“ Beijing Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ยท Tests: SKB264, Eribulin, Capecitabine, Gemcitabine, Vinorelbine 9MW2821 + Toripalimab vs 9MW2821 for 1st Line Locally Advanced or Metastatic Urothelial Carcinoma NCT06823427Phase 22 sites๐Ÿ“ Changsha๐Ÿ“ Nanjing Mabwell (Shanghai) Bioscience Co., Ltd. ยท Tests: 9MW2821, Toripalimab (JS001 ) A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression NCT06682793Phase 1, Phase 210 sites๐Ÿ“ Gilbert๐Ÿ“ La Jolla๐Ÿ“ Los Angeles A2 Biotherapeutics Inc. ยท Tests: A2B395, xT CDx with HLA-LOH assay A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Unresectable Locally Advanced or Recurrent Metastatic Triple-negative Breast Cancer NCT06471205Phase 21 site๐Ÿ“ Shanghai Sichuan Baili Pharmaceutical Co., Ltd. ยท Tests: BL-B01D1, PD-1 Monoclonal Antibody A Study of SI-B003 or BL-B01D1+SI-B003 in Patients With Unresectable Locally Advanced or Recurrent Metastatic HER2 Negative Breast Cancer NCT06042894Phase 21 site๐Ÿ“ Shanghai Sichuan Baili Pharmaceutical Co., Ltd. ยท Tests: BL-B01D1, SI-B003 Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC NCT05733598Phase 212 sites๐Ÿ“ Beverly Hills๐Ÿ“ La Jolla๐Ÿ“ Miami Replimune, Inc. ยท Tests: RP2, Bevacizumab, Atezolizumab, Durvalumab, RP2 Monotherapy First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer NCT06799065Phase 1, Phase 211 sites๐Ÿ“ Aurora๐Ÿ“ Sarasota๐Ÿ“ Detroit Accent Therapeutics ยท Tests: ATX-295, ATX-295 and bevacizumab (or biosimilar) Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial NCT05564377Phase 2484 sites๐Ÿ“ Birmingham๐Ÿ“ Mobile๐Ÿ“ Anchorage National Cancer Institute (NCI) ยท Tests: Alpelisib, Binimetinib, Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression NCT06051695Phase 1, Phase 212 sites๐Ÿ“ Gilbert๐Ÿ“ La Jolla๐Ÿ“ Los Angeles A2 Biotherapeutics Inc. ยท Tests: A2B694, A2B543, xT CDx with HLA-LOH Assay A Study of mRNA-4106 or mRNA-4200 Administered Alone or in Combination With Anti-Cancer Agents in Participants With Solid Tumors NCT06880549Phase 14 sites๐Ÿ“ Los Angeles๐Ÿ“ Grand Rapids๐Ÿ“ San Antonio ModernaTX, Inc. ยท Tests: mRNA-4106, Pembrolizumab, mRNA-4200 Parenting Support Intervention for Families Coping With Metastatic or Locally Recurrent Solid Tumor Diagnosis NCT05059678NA1 site๐Ÿ“ Houston M.D. Anderson Cancer Center ยท Tests: Best Practice, Educational Intervention, Questionnaire Administration A Dose Escalation and Expansion Study of [177Lu]Lu-SN201 in Participants With Advanced Cancer NCT06184035Phase 1, Phase 22 sites๐Ÿ“ Adelaide๐Ÿ“ Melbourne Spago Nanomedical AB ยท Tests: [177Lu]Lu-SN201 Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors NCT04777994Phase 130 sites๐Ÿ“ Tucson๐Ÿ“ New Haven๐Ÿ“ Baltimore Calico Life Sciences LLC ยท Tests: ABBV-CLS-484, Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitor (TKI), Programmed Cell Deatโ€ฆ YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer NCT07461454Phase 31 site๐Ÿ“ Shanghai MediLink Therapeutics (Suzhou) Co., Ltd. ยท Tests: YL202, Eribulin, Capecitabine, Gemcitabine, Vinorelbine Real-world Study of SKB264 Monotherapy or Combination Therapy in Recurrent or Metastatic HER2-negative Breast Cancer NCT06993506n/a19 sites๐Ÿ“ Hefei๐Ÿ“ Beijing๐Ÿ“ Beijing Cancer Institute and Hospital, Chinese Academy of Medical Sโ€ฆ ยท Tests: SKB264 Monotherapy or Combination Therapy
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy